Genentech awaits Avastin decision

All eyes are on the FDA today as Genentech waits with baited breath for the agency's decision on Avastin for breast cancer. In December an advisory committee voted 5-4 against the therapy. Avastin in combination with Bristol-Myers Squibb's Taxol delayed tumor growth much longer than Taxol alone. But the bad news was that the Avastin patients didn't live significantly longer, and suffered from more unpleasant side effects. Now it's up to the FDA to decide if slower tumor growth is enough to approve the drug if patients aren't living longer as a result. A positive decision could signify a new way of thinking about cancer treatments. If stopping tumor growth is enough for Avastin, then it could be enough for a host of other treatments currently in development.

Many breast cancer experts are eager to see the drug OK'd despite the committee's negative opinion. The FDA may break with the committee's recommendation, or simply delay it's decision until later this year. Avastin is Genentech's cash cow, bringing in $2.3 billion in sales last year.

- read this AP article for more

Related Articles:
Genentech faces crucial Avastin decision. Report
Will FDA care about new Avastin study? Report
EU blesses Avastin for broader use. Report
FDA: Avastin lackluster in breast cancer. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.